Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-07-18

Clinical Trial Update: Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing certolizumab pegol versus active comparator and placebo in plaque psoriasis; study completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Certolizumab pegol (certolizumab pegol)

Snippet

Sponsor: UCB Biopharma S.P.R.L. | Conditions: Psoriasis, Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2018-07-18